Baudax Bio to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
Baudax Bio, Inc. (NASDAQ:BXRX) will report its first quarter 2022 financial results on May 5, 2022. A conference call will be held at 8:30 a.m. ET to discuss these results and operational updates. The call can be accessed by dialing (866) 220-5595 for local and (615) 622-8062 for international calls. ANJESO, Baudax’s primary product, is the first 24-hour intravenous COX-2 preferential NSAID for managing moderate to severe pain. The company also has a pipeline of innovative pharmaceutical assets, including neuromuscular blocking agents.
- Scheduled earnings report for Q1 2022 on May 5, 2022.
- ANJESO is a unique intravenous NSAID, enhancing its market position.
- None.
MALVERN, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022. Baudax Bio will host a conference call and webcast at 8:30 a.m. ET on Thursday, May 5, 2022, to discuss the financial results and recent operational highlights.
To access the conference call, please dial (866) 220-5595 (local) or (615) 622-8062 (international) at least 10 minutes prior to the start time and refer to conference ID 1078117. A live audio webcast of the call will be available under “Events” in the Investor section of the Company’s website, https://www.baudaxbio.com/news-and-investors/events. An archived webcast will be available on the Company’s website approximately two hours after the event and will be available for 30 days.
About Baudax Bio
Baudax Bio is a pharmaceutical company focused on innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.
Forward Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. Such forward-looking statements reflect Baudax Bio’s expectations about its future performance and opportunities that involve substantial risks and uncertainties. When used herein, the words “anticipate,” “believe,” “estimate,” “may,” “upcoming,” “plan,” “target,” “goal,” “intend,” and “expect,” and similar expressions, as they relate to Baudax Bio or its management, are intended to identify such forward-looking statements. These forward-looking statements are based on information available to Baudax Bio as of the date of this press release, and are subject to a number of risks, uncertainties, and other factors that could cause Baudax Bio’s performance to differ materially from those expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, among other things, the risks and uncertainties included in Baudax Bio’s filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are based on information currently available to Baudax Bio, and Baudax Bio assumes no obligation to update any forward-looking statements except as required by applicable law.
CONTACTS:
Investor Relations Contact:
Argot Partners
Sam Martin / Kaela Ilami
(212) 600-1902
baudaxbio@argotpartners.com
Media Contact:
Argot Partners
David Rosen
(212) 600-1902
david.rosen@argotpartners.com
FAQ
When will Baudax Bio report its Q1 2022 results?
What time is the Baudax Bio conference call for Q1 2022 results?
How can I access the Baudax Bio Q1 2022 earnings call?
What is ANJESO?
What innovative products does Baudax Bio have aside from ANJESO?
